Physical instability, aggregation and conformational changes of recombinant human bone morphogenetic protein-2 (rhBMP-2)

International Journal of Pharmaceutics

Volumn 391, Issue 1-2, 2010, Pages 48-54

  Luca, Ludmila ^a   Capelle, Martinus A H ^a   Machaidze, Gia ^b   Arvinte, Tudor ^a   Jordan, Olivier ^a   Gurny, Robert ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

1,8 ANS; Aggregation; BMP 2; Electron microscopy; Fluorescence spectroscopy; Light scattering; Nile Red; Physical stability

Indexed keywords

8 ANILINO 1 NAPHTHALENESULFONIC ACID; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

ANISOTROPY; AQUEOUS SOLUTION; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; FLUORESCENCE; FLUORESCENCE SPECTROSCOPY; LIGHT SCATTERING; PH; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN STABILITY; TRANSMISSION ELECTRON MICROSCOPY;

BONE MORPHOGENETIC PROTEINS; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; FLUORESCENCE POLARIZATION; HUMANS; HYDROGEN-ION CONCENTRATION; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; SOLUBILITY; TRANSFORMING GROWTH FACTOR BETA;

EID: 77952885517     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.02.015     Document Type: Article

References (37)

1. Baron R., Neff L., Louvard D., Courtoy P.J. Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J. Cell Biol. 1985, 101:2210-2222.
2. Bergman K., Engstrand T., Hilborn J., Ossipov D., Piskounova S., Bowden T. Injectable cell-free template for bone-tissue formation. J. Biomed. Mater. Res. A 2008, 91:1111-1118.
3. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., Taddei N., Ramponi G., Dobson C.M., Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002, 416:507-511.
4. Capelle M.A., Brugger P., Arvinte T. Spectroscopic characterization of antibodies adsorbed to aluminium adjuvants: correlation with antibody vaccine immunogenicity. Vaccine 2005, 23:1686-1694.
5. Capelle M.A., Gurny R., Arvinte T. A high throughput protein formulation platform: case study of salmon calcitonin. Pharm. Res. 2009, 26:118-128.
6. Celeste A.J., Iannazzi J.A., Taylor R.C., Hewick R.M., Rosen V., Wang E.A., Wozney J.M. Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:9843-9847.
7. Chi E.Y., Krishnan S., Randolph T.W., Carpenter J.F. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm. Res. 2003, 20:1325-1336.
8. Demeule B., Gurny R., Arvinte T. Detection and characterization of protein aggregates by fluorescence microscopy. Int. J. Pharm. 2007, 329:37-45.
9. Demeule B., Lawrence M.J., Drake A.F., Gurny R., Arvinte T. Characterization of protein aggregation: the case of a therapeutic immunoglobulin. Biochim. Biophys. Acta 2007, 1774:146-153.
10. Friess W., Uludag H., Foskett S., Biron R. Bone regeneration with recombinant human bone morphogenetic protein-2 (rhBMP-2) using absorbable collagen sponges (ACS): influence of processing on ACS characteristics and formulation. Pharm. Dev. Technol. 1999, 4:387-396.
11. Friess W., Uludag H., Foskett S., Biron R., Sargeant C. Characterization of absorbable collagen sponges as rhBMP-2 carriers. Int. J. Pharm. 1999, 187:91-99.
12. Geiger M., Li R.H., Friess W. Collagen sponges for bone regeneration with rhBMP-2. Adv. Drug Deliv. Rev. 2003, 55:1613-1629.
13. Glatz C.E. Modeling of aggregation-precipitation phenomena. Stability of Protein Pharmaceuticals, Part A: Chemical and Physical Pathways of Protein Degradation 1992, 135-166. Plenum Press, New York. T.J. Ahern, M.C. Manning (Eds.).
14. Hawe A., Sutter M., Jiskoot W. Extrinsic fluorescent dyes as tools for protein characterization. Pharm. Res. 2008, 25:1487-1499.
15. Hollinger J., Wong M.E. The integrated processes of hard tissue regeneration with special emphasis on fracture healing. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 1996, 82:594-606.
16. Hsu H.P., Zanella J.M., Peckham S.M., Spector M. Comparing ectopic bone growth induced by rhBMP-2 on an absorbable collagen sponge in rat and rabbit models. J. Orthop. Res. 2006, 24:1660-1669.
17. Jiskoot W., Crommelin D. Methods for Structural Analysis of Protein Pharmaceuticals 2005, AAPS Press, Arlington.
18. Koenig B.B., Cook J.S., Wolsing D.H., Ting J., Tiesman J.P., Correa P.E., Olson C.A., Pecquet A.L., Ventura F., Grant R.A. Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells. Mol. Cell. Biol. 1994, 14:5961-5974.
19. Lakowicz J.R. Principles of Fluorescence Spectroscopy 2004, Springer Science, New York. 2nd ed.
20. Li R.H., Wozney J.M. Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol. 2001, 19:255-265.
21. Luginbuehl V., Meinel L., Merkle H.P., Gander B. Localized delivery of growth factors for bone repair. Eur. J. Pharm. Biopharm. 2004, 58:197-208.
22. Manning M.C., Patel K., Borchardt R.T. Stability of protein pharmaceuticals. Pharm. Res. 1989, 6:903-918.
23. Matulis D., Lovrien R. 1-Anilino-8-naphthalene sulfonate anion-protein binding depends primarily on ion pair formation. Biophys. J. 1998, 74:422-429.
24. Maus U., Andereya S., Gravius S., Siebert C.H., Ohnsorge J.A., Niedhart C. Lack of effect on bone healing of injectable BMP-2 augmented hyaluronic acid. Arch. Orthop. Trauma Surg. 2008, 128:1461-1466.
25. McKay W.F., Peckham S.M., Badura J.M. A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft). Int. Orthop. 2007, 31:729-734.
26. Middaugh C.R., Volkin D.B. Protein solubility. Stability of Protein Pharmaceuticals, Part A: Chemical and Physical Pathways of Protein Degradation 1992, 109-134. Plenum Press, New York. T.J. Ahern, M.C. Manning (Eds.).
27. Morris A.M., Watzky M.A., Finke R.G. Protein aggregation kinetics, mechanism, and curve-fitting: a review of the literature. Biochim. Biophys. Acta 2009, 1794:375-397.
28. Pellaud J., Schote U., Arvinte T., Seelig J. Conformation and self-association of human recombinant transforming growth factor-beta3 in aqueous solutions. J. Biol. Chem. 1999, 274:7699-7704.
29. Philo J.S. A critical review of methods for size characterization of non-particulate protein aggregates. Curr. Pharm. Biotechnol. 2009, 10:359-372.
30. Ruppert R., Hoffmann E., Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur. J. Biochem. 1996, 237:295-302.
31. Sackett D.L., Wolff J. Nile red as a polarity-sensitive fluorescent probe of hydrophobic protein surfaces. Anal. Biochem. 1987, 167:228-234.
32. Schwartz, D., 2005. Development of an Aqueous Suspension of Recombinant Human Bone morphogenetic Protein-2 (rhBMP-2). Ph.D. Thesis, University of Munich, Germany.
33. Senta H., Park H., Bergeron E., Drevelle O., Fong D., Leblanc E., Cabana F., Roux S., Grenier G., Faucheux N. Cell responses to bone morphogenetic proteins and peptides derived from them: biomedical applications and limitations. Cytokine Growth Factor Rev. 2009, 20:213-222.
34. Silver I.A., Murrills R.J., Etherington D.J. Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp. Cell Res. 1988, 175:266-276.
35. Uludag H., Friess W., Williams D., Porter T., Timony G., D'Augusta D., Blake C., Palmer R., Biron B., Wozney J. rhBMP-collagen sponges as osteoinductive devices: effects of in vitro sponge characteristics and protein pI on in vivo rhBMP pharmacokinetics. Ann. N. Y. Acad. Sci. 1999, 875:369-378.
36. Vallejo L.F., Rinas U. Optimized procedure for renaturation of recombinant human bone morphogenetic protein-2 at high protein concentration. Biotechnol. Bioeng. 2004, 85:601-609.
37. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 1999, 185:129-188.